Advertisement

Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction

  • Paola Mascia
  • Gianluigi Tanda
  • Sevil Yasar
  • Stephen J. Heishman
  • Steven R. Goldberg
Chapter
Part of the The Receptors book series (REC, volume 24)

Abstract

Recent research with animal models of human drug dependence has demonstrated that a receptor related to the endogenous cannabinoid system, the peroxisome proliferator-activated alpha nuclear receptor (PPARα), which regulates genes involved in lipid metabolism and inflammatory responses, is a viable target for treating nicotine dependence. The endogenous ligands for PPARα, oleoylethanolamide and palmitoylethanolamide, are structurally similar to anandamide, an endogenous ligand for cannabinoid receptors, and all three share the same degrading mechanism. Anandamide also has been reported to act at PPARα, as well as PPARγ, suggesting overlap and potential interactions between endogenous cannabinoid and PPAR receptor systems. In rat and nonhuman primate models of human tobacco dependence, PPARα agonists counteract neurochemical effects of nicotine in the brain that mediate nicotine’s rewarding effects and suppress nicotine self-administration behavior and relapse to nicotine-seeking behavior, suggesting PPARα agonists as a treatment for tobacco dependence. In other studies, the PPARγ agonists, pioglitazone and rosiglitazone, that belong to the class of thiazolidinediones (TZDs), which are used for the treatment of insulin resistance and type 2 diabetes, suppress alcohol-drinking behavior and relapse to alcohol-seeking behavior, as well as signs of alcohol withdrawal in rats, suggesting TZDs as a treatment for alcohol dependence. In addition, both PPARα and PPARγ activation suppress sensitization that develops the effects of psychostimulants and opioids when they are administered chronically. Since behavioral sensitization is believed to contribute to the development of drug dependence, these findings suggest a general utility of PPAR agonists as treatments for drug dependence.

Keywords

Ventral Tegmental Area Conditioned Place Preference Behavioral Sensitization Fatty Acid Amide Hydrolase Fatty Acid Amide Hydrolase Inhibition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

This research and preparation of the chapter was supported in part by the Intramural Research Program of the NIH, National Institute on Drug Abuse and by the Division of Geriatric Medicine and Gerontology of Johns Hopkins University School of Medicine.

References

  1. Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ (2009) Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 122(10):962.e1–962.e8CrossRefGoogle Scholar
  2. Ahn K, McKinney MK, Cravatt BF (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108(5):1687–1707PubMedCrossRefGoogle Scholar
  3. Avshalumov MV, Rice ME (2002) NMDA receptor activation mediates hydrogen peroxide-induced pathophysiology in rat hippocampal slices. J Neurophysiol 87(6):2896–2903PubMedGoogle Scholar
  4. Barish GD, Narkar VA, Evans RM (2006) PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116(3):590–597PubMedCrossRefGoogle Scholar
  5. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A (2004) The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54(2):65–71PubMedCrossRefGoogle Scholar
  6. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277(5329):1094–1097PubMedCrossRefGoogle Scholar
  7. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435PubMedCrossRefGoogle Scholar
  8. Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A (2008) Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav 93(4–5):666–670PubMedCrossRefGoogle Scholar
  9. Bernardo A, Ajmone-Cat MA, Levi G, Minghetti L (2003) 15-Deoxy-delta12,14-prostaglandin J2 regulates the functional state and the survival of microglial cells through multiple molecular mechanisms. J Neurochem 87(3):742–751PubMedCrossRefGoogle Scholar
  10. Bishop-Bailey D (2000) Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129(5):823–834PubMedCrossRefGoogle Scholar
  11. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, Appendino G, Saturnino C, Martin B, Razdan R, Di Marzo V (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761(2):205–212PubMedCrossRefGoogle Scholar
  12. Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137(1):354–366PubMedCrossRefGoogle Scholar
  13. Breese GR, Knapp DJ, Overstreet DH, Navarro M, Wills TA, Angel RA (2008) Repeated lipopolysaccharide (LPS) or cytokine treatments sensitize ethanol withdrawal-induced anxiety-like behavior. Neuropsychopharmacology 33(4):867–876PubMedCrossRefGoogle Scholar
  14. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem 82:615–624PubMedCrossRefGoogle Scholar
  15. Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z, Scheibal D, Abrams AL, Costello MR, Farahi J, Saxena S, Monterosso J, London ED (2009) Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology 34(2):282–289PubMedCrossRefGoogle Scholar
  16. Budzyńska B, Kruk M, Biała G (2009) Effects of the cannabinoid CB1 receptor antagonist AM 251 on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacol Rep 61(2):304–310PubMedGoogle Scholar
  17. Cahill K, Ussher M (2007) Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev (3):CD005353Google Scholar
  18. Caillé S, Parsons LH (2003) SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci 18(11):3145–3149PubMedCrossRefGoogle Scholar
  19. Caillé S, Parsons LH (2006) Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 31(4):804–813PubMedCrossRefGoogle Scholar
  20. Caillé S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH (2007) Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 27(14):3695–3702PubMedCrossRefGoogle Scholar
  21. Chang F, Jaber LA, Berlie HD, O’Connell MB (2007) Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 41:973–983PubMedCrossRefGoogle Scholar
  22. Chaperon F, Soubrié P, Puech AJ, Thiébot MH (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 135(4):324–332CrossRefGoogle Scholar
  23. Charpantier E, Wiesner A, Huh KH, Ogier R, Hoda JC, Allaman G, Raggenbass M, Feuerbach D, Bertrand D, Fuhrer C (2005) Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J Neurosci 25(43):9836–9849PubMedCrossRefGoogle Scholar
  24. Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM (2007) Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 27(4):791–795PubMedCrossRefGoogle Scholar
  25. Chen BT, Avshalumov MV, Rice ME (2001) H(2)O(2) is a novel, endogenous modulator of synaptic dopamine release. J Neurophysiol 85(6):2468–2476PubMedGoogle Scholar
  26. Cimini A, Cristiano L, Bernardo A, Benedetti E, Di Loreto S, Cerù MP (2003) Peroxisomes and PPARs in cultured neural cells. Adv Exp Med Biol 544:271–280PubMedCrossRefGoogle Scholar
  27. Cimini A, Benedetti E, Cristiano L, Sebastiani P, D’Amico MA, D’Angelo B, Di Loreto S (2005) Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130(2):325–337PubMedCrossRefGoogle Scholar
  28. Clapper JR, Vacondio F, King AR, Duranti A, Tontini A, Silva C, Sanchini S, Tarzia G, Mor M, Piomelli D (2009) A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem 4(9):1505–1513PubMedCrossRefGoogle Scholar
  29. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13(5–6):451–463PubMedCrossRefGoogle Scholar
  30. Cohen C, Kodas E, Griebel G (2005a) CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 81(2):387–395PubMedCrossRefGoogle Scholar
  31. Cohen C, Perrault G, Griebel G, Soubrié P (2005b) Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30(1): 145–155PubMedCrossRefGoogle Scholar
  32. Combs CK, Bates P, Karlo JC, Landreth GE (2001) Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem Int 39(5–6):449–457PubMedCrossRefGoogle Scholar
  33. Corrigall WA (1999) Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1(1):11–20PubMedCrossRefGoogle Scholar
  34. Corrigall WA, Coen KM (1989) Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 99(4):473–478CrossRefGoogle Scholar
  35. Corrigall WA, Coen KM (1994) Dopamine mechanisms play at best a small role in the nicotine discriminative stimulus. Pharmacol Biochem Behav 48(3):817–820PubMedCrossRefGoogle Scholar
  36. Cravatt BF, Lichtman AH (2002) The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 121(1–2):135–148PubMedCrossRefGoogle Scholar
  37. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384(6604):83–87PubMedCrossRefGoogle Scholar
  38. Cristiano L, Bernardo A, Cerù MP (2001) Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. J Neurocytol 30(8):671–683PubMedCrossRefGoogle Scholar
  39. Cullingford TE, Bhakoo K, Peuchen S, Dolphin CT, Patel R, Clark JB (1998) Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem 70(4):1366–1375PubMedCrossRefGoogle Scholar
  40. Dani JA (2001) Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 49(3):166–174PubMedCrossRefGoogle Scholar
  41. Dani JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70(4):439–446PubMedCrossRefGoogle Scholar
  42. Dasu MR, Park S, Devaraj S, Jialal I (2009) Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 150(8):3457–3464PubMedCrossRefGoogle Scholar
  43. De Biasi M, Dani JA (2011) Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci 34:105–130PubMedCrossRefGoogle Scholar
  44. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN (2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) 168(1–2):164–169CrossRefGoogle Scholar
  45. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090):1946–1949PubMedCrossRefGoogle Scholar
  46. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85(14):5274–5278PubMedCrossRefGoogle Scholar
  47. Di Chiara G, Acquas E, Tanda G, Cadoni C (1993) Drugs of abuse: biochemical surrogates of specific aspects of natural reward? Biochem Soc Symp 59:65–81PubMedGoogle Scholar
  48. Di Chiara G, Tanda G, Cadoni C, Acquas E, Bassareo V, Carboni E (1998) Homologies and differences in the action of drugs of abuse and a conventional reinforcer (food) on dopamine transmission: an interpretative framework of the mechanism of drug dependence. Adv Pharmacol 42:983–987PubMedCrossRefGoogle Scholar
  49. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372(6507):686–691PubMedCrossRefGoogle Scholar
  50. Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, Trabace L, Ciccocioppo R (2006) Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) 183(4):394–403CrossRefGoogle Scholar
  51. Everitt BJ, Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8(11):1481–1489PubMedCrossRefGoogle Scholar
  52. Farioli-Vecchioli S, Moreno S, Cerù MP (2001) Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system. J Neurocytol 30(1):21–33PubMedCrossRefGoogle Scholar
  53. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313(1):352–358PubMedCrossRefGoogle Scholar
  54. Fenner MH, Elstner E (2005) Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs 14(6):557–568PubMedCrossRefGoogle Scholar
  55. Fernandez-Espejo E, Ramiro-Fuentes S, Rodriguez de Fonseca F (2009) The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience 164(2):667–675PubMedCrossRefGoogle Scholar
  56. Ferré P (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53(suppl 1):S43–S50PubMedCrossRefGoogle Scholar
  57. Fiévet C, Fruchart JC, Staels B (2006) PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6(6):606–614PubMedCrossRefGoogle Scholar
  58. Filippatos TD, Elisaf MS (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother 12(12):1945–1958PubMedCrossRefGoogle Scholar
  59. Forget B, Barthélémy S, Saurini F, Hamon M, Thiébot M (2006) Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats. Psychopharmacology (Berl) 189(1):59-69CrossRefGoogle Scholar
  60. Forget B, Coen KM, Le Foll B (2009) Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration—comparison with CB(1) receptor blockade. Psychopharmacology (Berl) 205(4):613–624CrossRefGoogle Scholar
  61. Forman BM, Chen J, Evans RM (1996) The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci 804:266–275PubMedCrossRefGoogle Scholar
  62. Francis GA, Annicotte JS, Auwerx J (2003) PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 3(2):186–191PubMedCrossRefGoogle Scholar
  63. Freedland CS, Sharpe AL, Samson HH, Porrino LJ (2001) Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin Exp Res 25(2):277–282PubMedCrossRefGoogle Scholar
  64. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425(6953):90–93PubMedCrossRefGoogle Scholar
  65. Gamaleddin I, Guranda M, Goldberg SR, Le Foll B (2011) The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking induced by nicotine associated cues and nicotine priming, but does not affect nicotine-intake. Br J Pharmacol 164(6): 1652–1660PubMedCrossRefGoogle Scholar
  66. Gardner OS, Dewar BJ, Graves LM (2005) Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol Pharmacol 68(4):933–941PubMedCrossRefGoogle Scholar
  67. Garrett BE, Griffiths RR (2001) Intravenous nicotine and caffeine: subjective and physiological effects in cocaine abusers. J Pharmacol Exp Ther 296(2):486–494PubMedGoogle Scholar
  68. Gessa GL, Serra S, Vacca G, Carai MA, Colombo G (2005) Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol 40(1):46–53Google Scholar
  69. Gilgun-Sherki Y, Melamed E, Offen D (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40(8):959–975PubMedCrossRefGoogle Scholar
  70. Glass CK (2006) Going nuclear in metabolic and cardiovascular disease. J Clin Invest 116(3):556–560PubMedCrossRefGoogle Scholar
  71. Godlewski G, Alapafuja SO, Bátkai S, Nikas SP, Cinar R, Offertáler L, Osei-Hyiaman D, Liu J, Mukhopadhyay B, Harvey-White J, Tam J, Pacak K, Blankman JL, Cravatt BF, Makriyannis A, Kunos G (2010) Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol 17(11):1256–1266PubMedCrossRefGoogle Scholar
  72. Göttlicher M, Widmark E, Li Q, Gustafsson JA (1992) Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A 89(10):4653–4657PubMedCrossRefGoogle Scholar
  73. Granneman J, Skoff R, Yang X (1998) Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes. J Neurosci Res 51(5):563–573PubMedCrossRefGoogle Scholar
  74. Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B (2000) Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275(22):16638–16642PubMedCrossRefGoogle Scholar
  75. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98(7):3662–3665PubMedCrossRefGoogle Scholar
  76. Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR (2004) Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) 175(2):134–142CrossRefGoogle Scholar
  77. Heneka MT, Klockgether T, Feinstein DL (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20(18):6862–6867PubMedGoogle Scholar
  78. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):161–202PubMedCrossRefGoogle Scholar
  79. Hung MC, Hayase K, Yoshida R, Sato M, Imaizumi K (2001) Cerebral protein kinase C and its mRNA level in apolipoprotein E-deficient mice. Life Sci 69(12):1419–1427PubMedCrossRefGoogle Scholar
  80. Jackevicius CA, Tu JV, Demers V, Melo M, Cox J, Rinfret S, Kalavrouziotis D, Johansen H, Behlouli H, Newman A, Pilote L (2008) Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med 359(17):1802–1810PubMedCrossRefGoogle Scholar
  81. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM (2011) Use of fibrates in the United States and Canada. JAMA 305(12):1217–1224PubMedCrossRefGoogle Scholar
  82. Järbe TU, LeMay BJ, Olszewska T, Vemuri VK, Wood JT, Makriyannis A (2008) Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacol Biochem Behav 91(1):84–90PubMedCrossRefGoogle Scholar
  83. Järbe TU, Tai S, Lemay BJ, Nikas SP, Shukla VG, Zvonok A, Makriyannis A (2012) AM2389, a high-affinity, in vivo potent CB(1)-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacology (Berl) 220(2):417–426CrossRefGoogle Scholar
  84. Jehl-Pietri C, Bastie C, Gillot I, Luquet S, Grimaldi PA (2000) Peroxisome-proliferator-activated receptor delta mediates the effects of long-chain fatty acids on post-confluent cell proliferation. Biochem J 350(pt 1):93–98PubMedCrossRefGoogle Scholar
  85. Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D, Goldberg SR (2008) Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 64(11):930–937PubMedCrossRefGoogle Scholar
  86. Kainu T, Wikström AC, Gustafsson JA, Pelto-Huikko M (1994) Localization of the peroxisome proliferator-activated receptor in the brain. Neuroreport 5(18):2481–2485PubMedCrossRefGoogle Scholar
  87. Kalivas PW, O’Brien C (2008) Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 33(1):166–180PubMedCrossRefGoogle Scholar
  88. Kalman D, Smith SS (2005) Does nicotine do what we think it does? A meta-analytic review of the subjective effects of nicotine in nasal spray and intravenous studies with smokers and nonsmokers. Nicotine Tob Res 7(3):317–333PubMedCrossRefGoogle Scholar
  89. Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13:1813–1826PubMedCrossRefGoogle Scholar
  90. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9(1):76–81PubMedCrossRefGoogle Scholar
  91. Keating GM (2011) Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am J Cardiovasc Drugs 11(4):227–247PubMedCrossRefGoogle Scholar
  92. Kitamura Y, Shimohama S, Koike H, Kakimura J, Matsuoka Y, Nomura Y, Gebicke-Haerter PJ, Taniguchi T (1999) Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease brains. Biochem Biophys Res Commun 254(3):582–586PubMedCrossRefGoogle Scholar
  93. Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35(1):217–238PubMedCrossRefGoogle Scholar
  94. Krémarik-Bouillaud P, Schohn H, Dauça M (2000) Regional distribution of PPARbeta in the cerebellum of the rat. J Chem Neuroanat 19(4):225–232PubMedCrossRefGoogle Scholar
  95. Le Foll B, Goldberg SR (2004) Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15(13):2139–2143PubMedCrossRefGoogle Scholar
  96. Le Foll B, Goldberg SR (2005) Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl) 178(4):481–492CrossRefGoogle Scholar
  97. Le Foll B, Goldberg SR (2006) Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) 184(3–4):367–381CrossRefGoogle Scholar
  98. Le Foll B, Sokoloff P, Stark H, Goldberg SR (2005) Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 30(4):720–730PubMedGoogle Scholar
  99. Le Foll B, Gorelick DA, Goldberg SR (2009) The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 205(1):171–174CrossRefGoogle Scholar
  100. Lennon AM, Ramaugé M, Dessouroux A, Pierre M (2002) MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12–14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. J Biol Chem 277(33):29681–29685PubMedCrossRefGoogle Scholar
  101. Li X, Hoffman AF, Peng XQ, Lupica CR, Gardner EL, Xi ZX (2009) Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl) 204(1):1–11CrossRefGoogle Scholar
  102. Lleo A, Galea E, Sastre M (2007) Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 64(11):1403–1418PubMedCrossRefGoogle Scholar
  103. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67(1):15–19PubMedCrossRefGoogle Scholar
  104. Luchicchi A, Lecca S, Carta S, Pillolla G, Muntoni AL, Yasar S, Goldberg SR, Pistis M (2010) Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors. Addict Biol 15(3):277–288PubMedCrossRefGoogle Scholar
  105. Maccioni RB, Muñoz JP, Barbeito L (2001) The molecular bases of Alzheimer’s disease and other neurodegenerative disorders. Arch Med Res 32(5):367–381PubMedCrossRefGoogle Scholar
  106. Maeda T, Kiguchi N, Fukazawa Y, Yamamoto A, Ozaki M, Kishioka S (2007) Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice. Neuropsychopharmacology 32(5):1133–1140PubMedCrossRefGoogle Scholar
  107. Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29(4):225–232PubMedCrossRefGoogle Scholar
  108. Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, Fadda P, Barnes C, Redhi GH, Yasar S, Le Foll B, Tanda G, Piomelli D, Goldberg SR (2011) Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 69(7):633–641PubMedCrossRefGoogle Scholar
  109. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, Evrard A, Cazala P, Cormier A, Mameli-Engvall M, Dufour N, Cloëz-Tayarani I, Bemelmans AP, Mallet J, Gardier AM, David V, Faure P, Granon S, Changeux JP (2005) Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436(7047):103–107PubMedCrossRefGoogle Scholar
  110. Matsuura H, Adachi H, Smart RC, Xu X, Arata J, Jetten AM (1999) Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol Cell Endocrinol 147(1–2):85–92PubMedCrossRefGoogle Scholar
  111. Mazzola C, Medalie J, Scherma M, Panlilio LV, Solinas M, Tanda G, Drago F, Cadet JL, Goldberg SR, Yasar S (2009) Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem 16(5):332–337PubMedCrossRefGoogle Scholar
  112. Melis M, Pillolla G, Luchicchi A, Muntoni AL, Yasar S, Goldberg SR, Pistis M (2008) Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 28(51):13985–13994PubMedCrossRefGoogle Scholar
  113. Melis M, Carta S, Fattore L, Tolu S, Yasar S, Goldberg SR, Fratta W, Maskos U, Pistis M (2010) Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors. Biol Psychiatry 68(3):256–264PubMedCrossRefGoogle Scholar
  114. Mereu G, Yoon KW, Boi V, Gessa GL, Naes L, Westfall TC (1987) Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 141(3):395–399PubMedCrossRefGoogle Scholar
  115. Millar NS (2003) Assembly and subunit diversity of nicotinic acetylcholine receptors. Biochem Soc Trans 31(pt 4):869–874PubMedGoogle Scholar
  116. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tontini A, Piersanti G, Kathuria S, Piomelli D (2004) Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 47(21):4998–5008PubMedCrossRefGoogle Scholar
  117. Moraes LA, Piqueras L, Bishop-Bailey D (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110(3):371–385PubMedCrossRefGoogle Scholar
  118. Moreno S, Farioli-Vecchioli S, Ceru MP (2004) Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123:131–145PubMedCrossRefGoogle Scholar
  119. Morozov YM, Ben-Ari Y, Freund TF (2004) The spatial and temporal pattern of fatty acid amide hydrolase expression in rat hippocampus during postnatal development. Eur J Neurosci 20(2):459–466PubMedCrossRefGoogle Scholar
  120. Mounho BJ, Thrall BD (1999) The extracellular signal-regulated kinase pathway contributes to mitogenic and antiapoptotic effects of peroxisome proliferators in vitro. Toxicol Appl Pharmacol 159(2):125–133PubMedCrossRefGoogle Scholar
  121. Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, Fukushima Y, Peters JM, Gonzalez FJ, Aoyama T (2004) Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 40(4):972–980PubMedGoogle Scholar
  122. Narita M, Suzuki M, Kuzumaki N, Miyatake M, Suzuki T (2008) Implication of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine. Ann N Y Acad Sci 1141:96–104PubMedCrossRefGoogle Scholar
  123. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA, Maldonado R, Koob GF, Rodriguez de Fonseca F (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21(14):5344–5350PubMedGoogle Scholar
  124. Nestler EJ (2001) Molecular neurobiology of addiction. Am J Addict 10(3):201–217PubMedCrossRefGoogle Scholar
  125. O’Sullivan SE (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152(5):576–582PubMedCrossRefGoogle Scholar
  126. O’Sullivan SE, Kendall DA (2010) Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215(8):611–616PubMedCrossRefGoogle Scholar
  127. Perkins KA, Jetton C, Keenan J (2003) Common factors across acute subjective effects of nicotine. Nicotine Tob Res 5(6):869–875PubMedCrossRefGoogle Scholar
  128. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391(6663):173–177PubMedCrossRefGoogle Scholar
  129. Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C (1997) Common neural substrates for the addictive properties of nicotine and cocaine. Science 275(5296):83–86PubMedCrossRefGoogle Scholar
  130. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA (1997) Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390(6658):401–404PubMedCrossRefGoogle Scholar
  131. Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A 96(10):5802–5807PubMedCrossRefGoogle Scholar
  132. Pistis M, Melis M (2010) From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem 17(14):1450–1467PubMedCrossRefGoogle Scholar
  133. Plaza-Zabala A, Berrendero F, Suarez J, Bermudez-Silva FJ, Fernandez-Espejo E, Serrano A, Pavon FJ, Parsons LH, De Fonseca FR, Maldonado R, Robledo P (2010) Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse 64(5):379–389PubMedCrossRefGoogle Scholar
  134. Pontieri FE, Tanda G, Di Chiara G (1995) Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the “shell” as compared with the “core” of the rat nucleus accumbens. Proc Natl Acad Sci U S A 92(26):12304–12308PubMedCrossRefGoogle Scholar
  135. Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382(6588):255–257PubMedCrossRefGoogle Scholar
  136. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, ­virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301(3):1020–1024PubMedCrossRefGoogle Scholar
  137. Racchi M, Govoni S, Solerte SB, Galli CL, Corsini E (2001a) Dehydroepiandrosterone and the relationship with aging and memory: a possible link with protein kinase C functional machinery. Brain Res Brain Res Rev 37(1–3):287–293PubMedCrossRefGoogle Scholar
  138. Racchi M, Sironi M, Caprera A, König G, Govoni S (2001b) Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol Psychiatry 6(5):520–528PubMedCrossRefGoogle Scholar
  139. Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y; CIRRUS Study Group (2009) A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction 104(2):266–276Google Scholar
  140. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18(3):247–291PubMedCrossRefGoogle Scholar
  141. Robinson TE, Berridge KC (2008) The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci 363(1507):3137–3146PubMedCrossRefGoogle Scholar
  142. Rokos CL, Ledwith BJ (1997) Peroxisome proliferators activate extracellular signal-regulated kinases in immortalized mouse liver cells. J Biol Chem 272(20):13452–13457PubMedCrossRefGoogle Scholar
  143. Saluja I, Granneman JG, Skoff RP (2001) PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 33(3):191–204PubMedCrossRefGoogle Scholar
  144. Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD, Schwartz MW (2009) Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 150(2):707–712PubMedCrossRefGoogle Scholar
  145. Scherma M, Panlilio LV, Fadda P, Fattore L, Gamaleddin I, Le Foll B, Justinová Z, Mikics E, Haller J, Medalie J, Stroik J, Barnes C, Yasar S, Tanda G, Piomelli D, Fratta W, Goldberg SR (2008) Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther 327(2):482–490PubMedCrossRefGoogle Scholar
  146. Scherma M, Justinová Z, Zanettini C, Panlilio LV, Mascia P, Fadda P, Fratta W, Makriyannis A, Vadivel SK, Gamaleddin I, Le Foll B, Goldberg SR (2012) The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol 165(8):2539–2548PubMedCrossRefGoogle Scholar
  147. Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, Lichtman AH (2009) Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11(2):342–352CrossRefGoogle Scholar
  148. Shaham Y, Adamson LK, Grocki S, Corrigall WA (1997) Reinstatement and spontaneous recovery of nicotine seeking in rats. Psychopharmacology (Berl) 130(4):396–403CrossRefGoogle Scholar
  149. Shoaib M, Schindler CW, Goldberg SR, Pauly JR (1997) Behavioural and biochemical adaptations to nicotine in rats: influence of MK801, an NMDA receptor antagonist. Psychopharmacology (Berl) 134(2):121–130PubMedCrossRefGoogle Scholar
  150. Shoaib M (2008) The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 54(2):438–444PubMedCrossRefGoogle Scholar
  151. Singh ME, Verty AN, Price I, McGregor IS, Mallet PE (2004) Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. Neuropharmacology 47(8):1157–1169PubMedCrossRefGoogle Scholar
  152. Sink KS, Vemuri VK, Wood J, Makriyannis A, Salamone JD (2009) Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 91(3):303–306PubMedCrossRefGoogle Scholar
  153. Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, Markus EJ, Vemuri VK, Makriyannis A, Salamone JD (2010) Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20(2):112–122PubMedCrossRefGoogle Scholar
  154. Smith JW, Stolerman IP (2009) Recognising nicotine: the neurobiological basis of nicotine discrimination. Handb Exp Pharmacol 192:295–333PubMedCrossRefGoogle Scholar
  155. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003) The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306(1):93–102PubMedCrossRefGoogle Scholar
  156. Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, Vadivel SK, Makriyannis A, Goldberg SR (2007) The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 321(1):370–380PubMedCrossRefGoogle Scholar
  157. Solinas M, Goldberg SR, Piomelli D (2008) The endocannabinoid system in brain reward processes. Br J Pharmacol 154(2):369–383PubMedCrossRefGoogle Scholar
  158. Stienstra R, Duval C, Müller M, Kersten S (2007) PPARs, obesity, and inflammation. PPAR Res 2007:95974PubMedCrossRefGoogle Scholar
  159. Stopponi S, Somaini L, Cippitelli A, Cannella N, Braconi S, Kallupi M, Ruggeri B, Heilig M, Demopulos G, Gaitanaris G, Massi M, Ciccocioppo R (2011) Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry 69(7):642–649PubMedCrossRefGoogle Scholar
  160. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215(1):89–97PubMedCrossRefGoogle Scholar
  161. Sun Y, Alexander SP, Kendall DA, Bennett AJ (2006) Cannabinoids and PPARalpha signalling. Biochem Soc Trans 34(Pt 6):1095–1097PubMedGoogle Scholar
  162. Tanda G, Di Chiara G (1998) A dopamine-mu1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. Eur J Neurosci 10(3):1179–1187PubMedCrossRefGoogle Scholar
  163. Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276(5321): 2048–2050PubMedCrossRefGoogle Scholar
  164. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA (2004) Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306(5698):1029–1032PubMedCrossRefGoogle Scholar
  165. Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S, Plazzi PV, Park C, Kathuria S, Piomelli D (2003) Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 46(12): 2352–2360PubMedCrossRefGoogle Scholar
  166. Teruel T, Hernandez R, Benito M, Lorenzo M (2003) Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes. J Biol Chem 278(1):263–269PubMedCrossRefGoogle Scholar
  167. Thomas EA, Cravatt BF, Danielson PE, Gilula NB, Sutcliffe JG (1997) Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J Neurosci Res 50(6):1047–1052PubMedCrossRefGoogle Scholar
  168. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77:289–312PubMedCrossRefGoogle Scholar
  169. Tsuji T, Asanuma M, Miyazaki I, Miyoshi K, Ogawa N (2009) Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen. Neurochem Res 34(4):764–774PubMedCrossRefGoogle Scholar
  170. Vinklerová J, Nováková J, Sulcová A (2002) Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. J Psychopharmacol 16(2):139–143PubMedCrossRefGoogle Scholar
  171. Wise RA (1998) Drug-activation of brain reward pathways. Drug Alcohol Depend 51(1–2):13–22PubMedCrossRefGoogle Scholar
  172. Wise RA, Bozarth MA (1987) A psychomotor stimulant theory of addiction. Psychol Rev 94(4):469–492PubMedCrossRefGoogle Scholar
  173. Woods JW, Tanen M, Figueroa DJ, Biswas C, Zycband E, Moller DE, Austin CP, Berger JP (2003) Localization of PPARdelta in murine central nervous system: expression in oligodendrocytes and neurons. Brain Res 975(1–2):10–21PubMedCrossRefGoogle Scholar
  174. Xi ZX, Spiller K, Pak AC, Gilbert J, Dillon C, Li X, Peng XQ, Gardner EL (2008) Cannabinoid CB1 receptor antagonists attenuate cocaine’s rewarding effects: experiments with self-­administration and brain-stimulation reward in rats. Neuropsychopharmacology 33(7):1735–1745PubMedCrossRefGoogle Scholar
  175. Yin R, French ED (2000) A comparison of the effects of nicotine on dopamine and non-dopamine neurons in the rat ventral tegmental area: an in vitro electrophysiological study. Brain Res Bull 51(6):507–514PubMedCrossRefGoogle Scholar
  176. Zalcman S, Savina I, Wise RA (1999) Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats. Brain Res 847(2):276–283PubMedCrossRefGoogle Scholar
  177. Zambrzycka A, Alberghina M, Strosznajder JB (2002) Effects of aging and amyloid-beta peptides on choline acetyltransferase activity in rat brain. Neurochem Res 27(4):277–281PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Paola Mascia
    • 1
  • Gianluigi Tanda
    • 2
  • Sevil Yasar
    • 3
  • Stephen J. Heishman
    • 4
  • Steven R. Goldberg
    • 1
  1. 1.Department of Health and Human ServicesPreclinical Pharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of HealthBaltimoreUSA
  2. 2.Department of Health and Human ServicesPsychobiology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of HealthBaltimoreUSA
  3. 3.Division of Geriatric Medicine and GerontologyJohns Hopkins University School of MedicineBaltimoreUSA
  4. 4.Department of Health and Human ServicesNicotine Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of HealthBaltimoreUSA

Personalised recommendations